These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 38857273

  • 1. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
    Facha W, Tadesse T, Wolka E, Astatkie A.
    PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
    [Abstract] [Full Text] [Related]

  • 2. Attrition from care and its predictors among women exposed to dolutegravir- and efavirenz-based first-line antiretroviral therapy in Ethiopia: a before-and-after study.
    Facha W, Tadesse T, Wolka E, Astatkie A.
    Front Public Health; 2024; 12():1385441. PubMed ID: 39015389
    [Abstract] [Full Text] [Related]

  • 3. The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study.
    Gedefaw A, Tadesse BT, Berhan Y, Makonnen E, Vella S, Aklillu E.
    BMC Infect Dis; 2024 Sep 02; 24(1):901. PubMed ID: 39223552
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, Kaboggoza J, Sihlangu M, Coombs JA, Malaba T, Byamugisha J, Amara A, Gini J, Else L, Heiburg C, Hodel EM, Reynolds H, Mehta U, Byakika-Kibwika P, Hill A, Myer L, Lamorde M, Khoo S.
    PLoS Med; 2019 Sep 02; 16(9):e1002895. PubMed ID: 31539371
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S, Ajibola G, Maswabi K, Sakoi M, Bennett K, Hughes MD, Isaacson A, Diseko M, Zash R, Batlang O, Moyo S, Lockman S, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro R.
    J Acquir Immune Defic Syndr; 2020 Jul 01; 84(3):235-241. PubMed ID: 32195745
    [Abstract] [Full Text] [Related]

  • 9. Effect of Dolutegravir-Based First-Line Antiretroviral Therapy on Mother-to-Child Transmission of HIV Among HIV-Exposed Infants in Ethiopia: a Before-and-After Study.
    Facha W, Tadesse T, Wolka E, Astatkie A.
    HIV AIDS (Auckl); 2024 Jul 01; 16():203-215. PubMed ID: 38765704
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
    Tongtong Y, Shenghua H, Yin W, Lin C, Huanxia L, Chunrong L, Ruifeng Z, Xiaojing Y, Yuan Y, Yuanhong H, Ke Y.
    J Acquir Immune Defic Syndr; 2022 Oct 01; 91(S1):S1-S7. PubMed ID: 36094508
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, Gaolethe T, Petlo C, Lockman S, Holmes LB, Makhema J, Shapiro RL.
    Lancet Glob Health; 2018 Jul 01; 6(7):e804-e810. PubMed ID: 29880310
    [Abstract] [Full Text] [Related]

  • 13. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.
    Namayanja GA, Da Silva JF, Elur B, Nasirumbi PM, Raizes E, Ssempiira J, Nazziwa E, Nabukenya M, Sewanyana I, Balaba J, Ntale J, Calnan J, Birabwa E, Akao J, Mwangi C, Naluguza M, Ahimbisibwe A, Katureebe C, Nabadda S, Nelson L, Dirlikov E.
    PLoS One; 2024 Jul 01; 19(6):e0305129. PubMed ID: 38923981
    [Abstract] [Full Text] [Related]

  • 14. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N.
    J Int AIDS Soc; 2024 Feb 01; 27(2):e26216. PubMed ID: 38332525
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ.
    Lancet HIV; 2016 Nov 01; 3(11):e510-e520. PubMed ID: 27658869
    [Abstract] [Full Text] [Related]

  • 16. The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda.
    Wagner Z, Wang Z, Stecher C, Karamagi Y, Odiit M, Haberer JE, Linnemayr S.
    J Int AIDS Soc; 2024 Aug 01; 27(8):e26350. PubMed ID: 39155425
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
    Asare K, Sookrajh Y, van der Molen J, Khubone T, Lewis L, Lessells RJ, Naidoo K, Sosibo P, van Heerden R, Garrett N, Dorward J.
    Lancet Glob Health; 2024 Feb 01; 12(2):e282-e291. PubMed ID: 38142692
    [Abstract] [Full Text] [Related]

  • 18. Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.
    Bishop MD, Korutaro V, Boyce CL, Beck IA, Styrchak SM, Knowles K, Ziemba L, Brummel SS, Coletti A, Jean-Philippe P, Chakhtoura N, Vhembo T, Cassim H, Owor M, Fairlie L, Moyo S, Chinula L, Lockman S, Frenkel LM.
    J Acquir Immune Defic Syndr; 2024 Aug 01; 96(4):385-392. PubMed ID: 39175843
    [Abstract] [Full Text] [Related]

  • 19. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S.
    Lancet HIV; 2020 Mar 01; 7(3):e193-e200. PubMed ID: 32035041
    [Abstract] [Full Text] [Related]

  • 20. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A, Laker M, Odongpiny EAL, Ajok F, Onen H, Kalule I, Kajubi P, Seden K, Owarwo N, Kiragga A, Armstrong-Hough M, Katahoire A, Mujugira A, Lamorde M, Castelnuovo B.
    BMC Infect Dis; 2021 Nov 13; 21(1):1154. PubMed ID: 34774018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.